Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

IIb's are not IIb's.

D J Kereiakes1, J P Runyon, T M Broderick

  • 1The Carl and Edyth Lindner Center for Research and Education, Cincinnati, Ohio, USA.

The American Journal of Cardiology
|May 4, 2000
PubMed
Summary

Platelet glycoprotein IIb/IIIa inhibitors improve outcomes in cardiovascular procedures. However, agents like abciximab show distinct receptor binding and survival benefits compared to others, suggesting unique mechanisms beyond simple receptor blockade.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials.

Heart (British Cardiac Society)·2003
Same author

The platelet function dose-response to abciximab during percutaneous coronary revascularization is variable.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2001
Same author

Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban.

Journal of thrombosis and thrombolysis·2001
Same author

Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.

American heart journal·2001
Same author

Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease.

American heart journal·2001
Same author

Low molecular weight heparin therapy for percutaneous coronary intervention: a practice in evolution.

Journal of thrombosis and thrombolysis·2001

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Biochemistry

Background:

  • Platelet glycoprotein (GP) IIb/IIIa receptor blockade is crucial for improving outcomes in percutaneous coronary intervention (PCI) and acute coronary syndromes.
  • Current GP IIb/IIIa inhibitors exhibit significant differences in pharmacodynamics, pharmacokinetics, and receptor affinity.

Purpose of the Study:

  • To compare the distinct binding characteristics and clinical outcomes associated with different GP IIb/IIIa receptor antagonists.
  • To investigate the mechanisms underlying observed survival advantages with specific agents.

Main Methods:

  • Analysis of pharmacodynamic and pharmacokinetic profiles of abciximab, eptifibatide, and tirofiban.
  • Examination of differential binding sites on the GP IIb/IIIa receptor.

Related Experiment Videos

  • Review of clinical trial data and practice outcomes comparing these agents post-PCI.

    • Main Results:

    • Abciximab exhibits high affinity and prolonged receptor action, unlike eptifibatide and tirofiban which have lower affinity and shorter durations.
    • Abciximab binds to additional receptors (CD11b/18 and αvβ3), potentially contributing to its observed survival advantage post-PCI.
    • No survival benefit has been consistently observed with eptifibatide or tirofiban therapy for PCI.

    Conclusions:

    • The common affinity for the GP IIb/IIIa receptor does not fully explain agent-specific benefits.
    • Abciximab's unique binding properties and additional receptor interactions may underlie its superior survival outcomes in PCI.
    • Further research is needed to elucidate the precise mechanisms driving differential clinical benefits among GP IIb/IIIa inhibitors.